Abstract
Aminoglutethimide (OrimetenR) was first introduced as an anticonvulsant (EliptenR) in the United States in 1960. It was withdrawn in 1966 following reports of a small number of adverse effects in children including adrenocortical insufficiency, which appeared to be associated with the experimental evidence of an inhibitory effect of the drug on steroid synthesis in the adrenal cortex. It was not until 1969 that the use of the compound in metastatic breast cancer was first reported and the purpose of this review is to describe the current position of aminoglutethimide in the management of this condition and other hormone-dependent tumours, and to outline possible future developments based on the outcome of ongoing and proposed research.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Editor information
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Jackson, I.M. (1984). Aminoglutethimide (OrimetenR): The Present and the Future. In: Harrap, K.R., Davis, W., Calvert, A.H. (eds) Cancer Chemotherapy and Selective Drug Development. Developments in Oncology, vol 23. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3837-6_73
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3837-6_73
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3839-0
Online ISBN: 978-1-4613-3837-6
eBook Packages: Springer Book Archive